| Identifying novel protein‐protein interactions using co‐immunoprecipitation and mass spectroscopy RB Free, LA Hazelwood, DR Sibley Current protocols in neuroscience 46 (1), 5.28. 1-5.28. 14, 2009 | 137 | 2009 |
| D1 and D2 dopamine receptor expression is regulated by direct interaction with the chaperone protein calnexin RB Free, LA Hazelwood, DM Cabrera, HN Spalding, Y Namkung, ... Journal of Biological Chemistry 282 (29), 21285-21300, 2007 | 106 | 2007 |
| D1-D2 dopamine receptor synergy promotes calcium signaling via multiple mechanisms LS Chun, RB Free, TB Doyle, XP Huang, ML Rankin, DR Sibley Molecular pharmacology 84 (2), 190-200, 2013 | 91 | 2013 |
| Discovery and Characterization of a G Protein–Biased Agonist That Inhibits β-Arrestin Recruitment to the D2 Dopamine Receptor RB Free, LS Chun, AE Moritz, BN Miller, TB Doyle, JL Conroy, A Padron, ... Molecular pharmacology 86 (1), 96-105, 2014 | 88 | 2014 |
| Identification of G protein-biased agonists that fail to recruit β-arrestin or promote internalization of the D1 dopamine receptor JL Conroy, RB Free, DR Sibley ACS chemical neuroscience 6 (4), 681-692, 2015 | 74 | 2015 |
| New roles for dopamine D2 and D3 receptors in pancreatic beta cell insulin secretion ZJ Farino, TJ Morgenstern, A Maffei, M Quick, AJ De Solis, ... Molecular psychiatry 25 (9), 2070-2085, 2020 | 70 | 2020 |
| Ring E analogs of methyllycaconitine (MLA) as novel nicotinic antagonists SC Bergmeier, DJ Lapinsky, RB Free, DB McKay Bioorganic & medicinal chemistry letters 9 (15), 2263-2266, 1999 | 69 | 1999 |
| Reciprocal modulation of function between the D1 and D2 dopamine receptors and the Na+, K+-ATPase LA Hazelwood, RB Free, DM Cabrera, M Skinbjerg, DR Sibley Journal of Biological Chemistry 283 (52), 36441-36453, 2008 | 65 | 2008 |
| Dopamine regulates pancreatic glucagon and insulin secretion via adrenergic and dopaminergic receptors D Aslanoglou, S Bertera, M Sánchez-Soto, R Benjamin Free, J Lee, ... Translational psychiatry 11 (1), 59, 2021 | 64 | 2021 |
| Advances and challenges in the search for D2 and D3 dopamine receptor-selective compounds AE Moritz, RB Free, DR Sibley Cellular signalling 41, 75-81, 2018 | 58 | 2018 |
| 3.1 Molecular pharmacology of the dopamine receptors ML RANKIN, LA Hazelwood, RB Free, EB Rex, RA Roof, DR Sibley Dopamine handbook 63, 2010 | 51 | 2010 |
| Structure–activity studies with ring E analogues of methyllycaconitine on bovine adrenal α3β4* nicotinic receptors DL Bryant, RB Free, SM Thomasy, DJ Lapinsky, KA Ismail, SB McKay, ... Neuroscience research 42 (1), 57-63, 2002 | 51 | 2002 |
| Synthesis and pharmacological characterization of novel trans-cyclopropylmethyl-linked bivalent ligands that exhibit selectivity and allosteric pharmacology at the dopamine D3 … V Kumar, AE Moritz, TM Keck, A Bonifazi, MP Ellenberger, CD Sibley, ... Journal of medicinal chemistry 60 (4), 1478-1494, 2017 | 48 | 2017 |
| Identification of positive allosteric modulators of the D1 dopamine receptor that act at diverse binding sites KD Luderman, JL Conroy, RB Free, N Southall, M Ferrer, M Sanchez-Soto, ... Molecular Pharmacology 94 (4), 1197-1209, 2018 | 38 | 2018 |
| Novel Analogues of (R)-5-(Methylamino)-5,6-dihydro-4H-imidazo[4,5,1-ij]quinolin-2(1H)-one (Sumanirole) Provide Clues to Dopamine D2/D3 Receptor … MF Zou, TM Keck, V Kumar, P Donthamsetti, M Michino, C Burzynski, ... Journal of medicinal chemistry 59 (7), 2973-2988, 2016 | 36 | 2016 |
| A structural basis for how ligand binding site changes can allosterically regulate GPCR signaling and engender functional selectivity M Sanchez-Soto, RK Verma, BKA Willette, EC Gonye, AM Moore, ... Science signaling 13 (617), eaaw5885, 2020 | 35 | 2020 |
| Structural basis for Na+-sensitivity in dopamine D2 and D3 receptors M Michino, RB Free, TB Doyle, DR Sibley, L Shi Chemical communications 51 (41), 8618-8621, 2015 | 34 | 2015 |
| Discovery, Optimization, and Characterization of Novel D2 Dopamine Receptor Selective Antagonists J Xiao, RB Free, E Barnaeva, JL Conroy, T Doyle, B Miller, ... Journal of medicinal chemistry 57 (8), 3450-3463, 2014 | 34 | 2014 |
| (-)-Stepholidine is a potent pan-dopamine receptor antagonist of both G protein-and β-arrestin-mediated signaling JA Meade, RB Free, NR Miller, LS Chun, TB Doyle, AE Moritz, JL Conroy, ... Psychopharmacology 232, 917-930, 2015 | 32 | 2015 |
| Investigation of the binding and functional properties of extended length D3 dopamine receptor-selective antagonists CA Furman, RA Roof, AE Moritz, BN Miller, TB Doyle, RB Free, AK Banala, ... European Neuropsychopharmacology 25 (9), 1448-1461, 2015 | 28 | 2015 |
